Medindia

X

Reportlinker Adds Chronic Kidney Disease - Drug Pipeline Analysis and Market Forecasts to 2016

Wednesday, March 17, 2010 Research News J E 4
Advertisement


NEW YORK, March 16 Reportlinker.com announces that a new market research report is available in its catalogue:

Chronic Kidney Disease - Drug Pipeline Analysis and Market Forecasts to 2016

http://www.reportlinker.com/p0182975/Chronic-Kidney-Disease---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html

Description

Chronic Kidney Disease - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

"Chronic Kidney Disease - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global chronic kidney disease market. This pharma report identifies the key trends shaping and driving the global chronic kidney disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global chronic kidney disease sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.


- Annualized global chronic kidney disease market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.

- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.

- Pipeline analysis data split across different phases by mechanism of action and emerging trends. Key classes of mechanism of action phosphate binders, erythropoietin (EPO) activators, nutrition supplements, iron replacement therapy, PTH synthesis inhibitor, Angiotensin Converting Enzyme (ACE) Inhibitor, endothelin antagonist, Angiotensin II Receptor Blocker, Antioxidant Inflammation Modulator, Direct renin inhibitor, IMPDH Inhibitor, Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor.

- Analysis of the current and future competition in the global chronic kidney disease market. Key market players covered include Reata Pharmaceuticals, Keryx Pharmaceuticals, Cytochroma Inc, Affymax, Ineos Healthcare, Merck & Co Inc, Pfizer, Novartis AG, Amgen and Abbott Plc.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future chronic kidney disease market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease market.

- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global chronic kidney disease market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global chronic kidney disease market landscape? - Identify, understand and capitalize.

Companies Mentioned

Novartis AG

Reata Pharmaceuticals, Inc

Mitsubishi Tanabe Pharma Corporation

Cytochroma Inc

Keryx Biopharmaceuticals

Astellas Pharma Inc

FibroGen

Table of Contents

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 4

2 Chronic Kidney Disease Market: Market Characterization 5

2.1 Overview 5

2.2 Chronic Kidney Disease Market Size 5

2.3 Chronic Kidney Disease Market Forecast and CAGR 5

2.4 Drivers and Barriers for the Chronic Kidney Disease Market 7

2.4.1 Drivers for the Chronic Kidney Disease Market 7

2.4.2 Barriers for the Chronic Kidney Disease Market 8

2.5 Opportunity and Unmet Need 8

2.6 Key Takeaway 9

3 Chronic Kidney Disease Market: Competitive Assessment 10

3.1 Overview 10

3.2 Strategic Competitor Assessment 10

3.3 Product Profiles of the Major Marketed Products in the Chronic Kidney Disease Market 11

3.3.1 Renagel (sevelamer hydrochloride) 11

3.3.2 Sensipar (Cinacalcet hydrochloride) 12

3.3.3 Feraheme (ferumoxytol) 12

3.3.4 Fosrenol (lanthanum carbonate hydrate) 13

3.4 Key Takeaway 15

4 Chronic Kidney Disease Market: Pipeline Assessment 16

4.1 Overview 16

4.2 Strategic Pipeline Assessment 16

4.2.1 Technology Trends Analytic Framework 16

4.3 Chronic Kidney Disease Therapeutics - Promising Drugs under Clinical Development 18

4.4 Molecule Profile for Promising Drugs under Clinical Development 18

4.4.1 Bardoxolone methyl 18

4.4.2 MCI-196 19

4.4.3 CTA018 20

4.4.4 AST-120 (Kremezin) 21

4.5 Chronic Kidney Disease Therapeutics Market - Clinical Pipeline by Mechanism of Action 22

4.6 Chronic Kidney Disease Pipeline - Pipeline by Clinical Phases of Development 23

4.6.1 Chronic Kidney Disease Therapeutics - Phase III Clinical Pipeline 23

4.6.2 Chronic Kidney Disease Therapeutics - Phase II Clinical Pipeline 26

4.6.3 Chronic Kidney Disease Therapeutics - Phase I Clinical Pipeline 29

4.6.4 Chronic Kidney Disease Therapeutics - Drug Discovery and Preclinical Pipeline 29

4.6.5 Discontinued / Suspended Drugs for Chronic Kidney Disease 30

4.7 Key Takeaway 30

5 Chronic Kidney Disease Market: Implications for Future Market Competition 31

6 Chronic Kidney Disease Market: Future Players in the Chronic Kidney Disease Market 33

6.1 Introduction 33

6.2 Novartis AG 33

6.2.1 Company Overview 33

6.2.2 Chronic Kidney Disease Portfolio 34

6.3 Reata Pharmaceuticals, Inc 34

6.3.1 Company Overview 34

6.3.2 Chronic Kidney Disease Portfolio 34

6.4 Mitsubishi Tanabe Pharma Corporation 34

6.4.1 Company Overview 34

6.4.2 Business Description 35

6.4.3 Chronic Kidney Disease Portfolio 35

6.5 Cytochroma Inc 35

6.5.1 Company Overview 35

6.5.2 Chronic Kidney Disease Portfolio 36

6.6 Keryx Biopharmaceuticals 36

6.6.1 Company Overview 36

6.6.2 Business Description 36

6.6.3 Chronic Kidney Disease Portfolio 37

6.7 Astellas Pharma Inc. 37

6.7.1 Company Overview 37

6.7.2 Business Description 38

6.7.3 Chronic Kidney Disease Portfolio 38

6.8 FibroGen 39

6.8.1 Company Overview 39

6.8.2 Chronic Kidney Disease Portfolio 39

7 Chronic Kidney Disease Market: Appendix 40

7.1 Market Definition 40

7.2 Abbreviations 40

7.3 Research Methodology 40

7.3.1 Coverage 41

7.3.2 Secondary Research 41

7.3.3 Forecasting 42

7.3.4 Primary Research 44

7.3.5 Expert Panels 45

7.4 Contact Us 45

7.5 Disclaimer 45

7.6 Sources 45

List of Tables

1.1 List of Tables

Table 1: Global Chronic Kidney Disease Market Forecast ($bn), 2001-2009 6

Table 2: Global Chronic Kidney Disease Market Forecast ($bn), 2009-2016 7

Table 3: Marketed Product Analysis in the Chronic Kidney Disease Market, 2010 15

Table 4: Chronic Kidney Disease Therapeutics - Most Promising Drugs under Clinical Development, 2010 18

Table 5: Chronic Kidney Disease Pipeline, Phase III, 2010 23

Table 6: Chronic Kidney Disease Pipeline, Phase II, 2010 26

Table 7: Chronic Kidney Disease Pipeline, Phase I, 2010 29

Table 8: Chronic Kidney Disease Pipeline, Drug Discovery and Preclinical Phase, 2010 29

Table 9: Chronic Kidney Disease Pipeline, Discontinued / Suspended Drugs, 2010 30

Table 10: Novartis AG - Chronic Kidney Disease Pipeline, 2010 34

Table 11: Reata Pharmaceuticals - Chronic Kidney Disease Pipeline, 2010 34

Table 12: Mitsubishi Tanabe Pharma Corporation - Chronic Kidney Disease Pipeline, 2010 35

Table 13: Cytochroma - Chronic Kidney Disease Pipeline, 2010 36

Table 14: Keryx Biopharmaceuticals - Chronic Kidney Disease Pipeline, 2010 37

Table 15: Astellas - Chronic Kidney Disease Pipeline, 2010 38

Table 16: Fibrogen - Chronic Kidney Disease Pipeline, 2010 39

List of Figures

1.2 List of Figures

Figure 1: Global Chronic Kidney Disease Market Revenues ($bn), 2001-2009 6

Figure 2: Global Chronic Kidney Disease Market Forecast ($bn), 2009-2016 7

Figure 3: Opportunity and Unmet Need in the Chronic Kidney Disease Market, 2010 9

Figure 4: Strategic Competitor Assessment of the Marketed Products for Chronic Kidney Disease, 2010 10

Figure 5: Technology Trends Analytic Framework of the Chronic Kidney Disease Pipeline, 2010 17

Figure 6: Technology Trends Analytic Framework of the Chronic Kidney Disease Pipeline - Description, 2010 17

Figure 7: Chronic Kidney Disease Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2010 22

Figure 8: Chronic Kidney Disease Pipeline by Phase of Clinical Development, 2010 23

Figure 9: Implications for Future Market Competition in the Chronic Kidney Disease Market, 2010 31

Figure 10: Chronic Kidney Disease Therapeutics Market - Clinical Pipeline by Company, 2010 33

Figure 11: GlobalData Methodology 41

Figure 12: GlobalData Market Forecasting Model 44

To order this report:

Pharmaceutical Industry: Chronic Kidney Disease - Drug Pipeline Analysis and Market Forecasts to 2016

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Contact Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Microcrystalline Cellulose (MCC)...
S
R&D Investment by U.S. Biopharmaceutical Companies...